Halpern Bruno, Oliveira Eduardo S L, Faria André M, Halpern Alfredo, Melo Maria Edna de, Cercato Cintia, Mancini Marcio C
Obesity & Metabolic Syndrome Group, Discipline of Endocrinology & Metabolism, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, 7º andar, sala 7037, 05403-000 - São Paulo, SP, Brazil.
Laboratory of Carbohydrates and Radioimuneassay/LIM-18, Faculty of Medicine, University of São Paulo, Av. Dr Arnaldo, 455 01246-903 - São Paulo, SP, Brazil.
Pharmaceuticals (Basel). 2010 Jul 27;3(8):2398-2415. doi: 10.3390/ph3082398.
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.
肥胖是一种与发病率和死亡率过高相关的慢性疾病。然而，目前的临床治疗效果令人失望，减肥失败或体重反弹的发生率非常高，且仅有两种药物（奥利司他和西布曲明）被批准长期使用。联合用药可能是其治疗的一种选择，但是，尽管在临床实践中广泛使用，但文献中可用于验证的数据却很少。我们的综述重点关注联合用药的原理、优缺点；常用的联合用药情况（有无相关研究）；以及主要由制药行业正在研究的联合用药的新前景。
